Insider Trading History of Haas Jason

The following table details the insider trading activities (stock purchases, stock sales, and stock option exercises) of Haas Jason since 2023. This trader's CIK number is 1883821. At the time of last reporting, Haas Jason was the Chief Financial Officer of Odyssey Therapeutics, Inc.. (stock ticker symbol ODTX). Also see all insider trading activities at Odyssey Therapeutics, Inc..

Note that in the past Haas Jason also reported insider trading activities as an insider of the following companies:

Yearly summary of insider trading at Syros Pharmaceuticals, Inc. (SYRS) by Haas Jason

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2024 SYRS 100,000 $161,217 137,803 $28,938 34,208 $0
2023 SYRS 0 $0 0 $0 2,000 $0

Yearly summary of insider trading at Odyssey Therapeutics, Inc. (ODTX) by Haas Jason

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2026 ODTX 1,000 $20,000 0 $0 0 $0


Insider trading activities at 2 companies by Haas Jason:

1. Syros Pharmaceuticals, Inc. (SYRS)

2. Odyssey Therapeutics, Inc. (ODTX)

Table 1. Insider trading of Syros Pharmaceuticals, Inc. (SYRS) by Haas Jason

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2024-11-18 SYRS Sale 137,803 .21 28,938
2024-10-31 SYRS Option Ex 18,875 .00 0
2024-09-12 SYRS Buy 45,344 1.68 75,996
2024-09-11 SYRS Buy 19,293 1.58 30,444
2024-09-10 SYRS Buy 35,363 1.55 54,777
2024-03-31 SYRS Option Ex 15,333 .00 0
2023-03-31 SYRS Option Ex 2,000 .00 0

Table 2. Insider trading of Odyssey Therapeutics, Inc. (ODTX) by Haas Jason

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2026-05-08 ODTX Buy 1,000 20.00 20,000

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Haas Jason (Chief Financial Officer of Odyssey Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.



©2023, insider-monitor.com. All rights reserved.